arrow
F

F. Aubin

besancon franche-comte university hospital
H指数:75
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS)

III期黑色素瘤切除术后辅助治疗的生存结局:真实世界队列研究(TAMARIS)的结果

2026-06-250
PRE
Combined Oral Ivermectin and 5% Permethrin Cream to Treat Severe Scabies

联合口服伊维菌素和5%氯菊酯乳膏治疗重症疥疮

2026-05-071
PRE
GWTC-4.0: An Introduction to Version 4.0 of the Gravitational-Wave Transient Catalog

GWTC-4.0:引力波暂现源目录4.0版本的介绍

2025-12-090
OA
Impact of BMI and quality of life on dupilumab response in chronic prurigo: A cohort study

体重指数(BMI)和生活质量对慢性瘙痒性皮炎患者度普利尤单抗(dupilumab)疗效的影响:一项队列研究

2025-11-100
PRE
Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients

晚期 Merkel 细胞癌患者生存结局及对免疫检查点抑制剂的应答:一项包含 81 例患者的回顾性研究

2025-08-020
PRE
A multicentre pragmatic randomized controlled trial comparing 50% salicylic acid, liquid nitrogen, 5% 5-fluorouracil cream, and 5% imiquimod cream in previously treated plantar warts. The VRAIE (VeRrues plAntaIres en villE) study

一项多中心实用型随机对照试验,比较50%水杨酸、液氮、5% 5-氟尿嘧啶乳膏和5%咪喹莫特乳膏在既往治疗过的跖疣中的应用。VRAIE(VeRrues plAntaIres en villE)研究

2025-07-300
OAAI
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: a nationwide real-life study in France (NEOMEL)

Nardin C,Cavalieri C,Lebbé C,Gérard E,Puyraveau M,Vergara R,等人. 可切除III/IV期黑色素瘤患者的新辅助免疫检查点抑制剂治疗:一项法国全国性真实世界研究(NEOMEL). 英国皮肤病学杂志. (2025) 7:ljaf268. doi: 10.1093/bjd/ljaf268.

2025-07-140
PRE
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study

联合使用encorafenib和binimetinib,随后使用ipilimumab和nivolumab,与直接使用ipilimumab和nivolumab相比,在携带BRAFV600E或BRAFV600K突变的晚期黑色素瘤患者中的疗效比较(EBIN):一项国际、开放标签、随机对照、二期研究

2025-05-280
PRE
TIE-2–Expressing Monocytic Myeloid-Derived Suppressor Cells Are Involved in Resistance to Anti–PD-1 Therapy Mediated by Angiopoietin 2 in Patients with Melanoma

TIE-2–表达的单核髓源性抑制细胞通过Angiopoietin 2参与黑色素瘤患者对PD-1抑制疗法产生抗性。

2025-03-180
PRE